Compound class:
Synthetic organic
Comment: TAK-070 from Takeda shows partial reduction in Aβ as well as increase in sAPPα in animal models. The noncompetitive BACE1 inhibition may be sufficient to modify amyloid pathology and ameliorate cognitive deficits in Alzheimer's Diseases without causing potential adverse events by complete BACE1 ablation.[1]
![]() Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
Bioactivity Comments |
Lineweaver–Burk plot analysis indicated that TAK-070 inhibits BACE1 in a noncompetitive manner but at low potency. It did not inhibit cathepsin D, E, renin, γ-secretase nor activated of human TACE in cell-free assays.[1] |
Selectivity at enzymes | ||||||||||||||||||||||||||||||||||
Key to terms and symbols | Click column headers to sort | |||||||||||||||||||||||||||||||||
|